Botensilimab clinical trials
Also written AGEN1181.
How each study uses botensilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the botensilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2025 (8); 2 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 8 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 26
City of Hope Medical Center (5) · Agenus Inc. (4) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · Northwestern University (1) · Bruno Bockorny (1) · Immune Oncology Research Institute (1) · University of Colorado, Denver (1)
Often tested with
Tested in the same studies.
Balstilimab (26) · Dalutrafusp alfa (1) · Zalifrelimab (1) · Trastuzumab deruxtecan (1) · Durvalumab (1) · Panitumumab (1) · Sotorasib (1) · Vorbipiprant (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8
Studies that test botensilimab.
- Jan 2027Botensilimab, Balstilimab, and SBRT in Colorectal CancerEarly Phase 1 · Massachusetts General Hospital
- Jan 2027Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerPhase 1 · University of Southern California
- Apr 2027Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasPhase 2 · University of Colorado, Denver
- May 2027Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)Phase 2 · Gruppo Oncologico del Nord-Ovest
- Jun 2027RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerPhase 2 · Dana-Farber Cancer Institute
- Jun 2027FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerPhase 1/2 · City of Hope Medical Center
- Sep 2027A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerPhase 2 · Agenus Inc.
- Nov 2027FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryPhase 2 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses botensilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 30
- A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06843434Written as Botensilimab
- RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT07735624Written as Botensilimab
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07516366Written as Botensilimab
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3RecruitingPhase 2City of Hope Medical CenterNCT07595874Written as Botensilimab
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07551596Written as Botensilimab
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07227636Written as Botensilimab
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Botensilimab
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-RadiationRecruitingPhase 2Benjamin SpielerNCT06843551Written as Botensilimab
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06411691Written as Botensilimab
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryRecruitingPhase 2City of Hope Medical CenterNCT06780787Written as Botensilimab
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197Written as Botensilimab
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingEarly Phase 1Northwell HealthNCT07193862Written as Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Botensilimab, Balstilimab, and SBRT in Colorectal CancerRecruitingEarly Phase 1Massachusetts General HospitalNCT07128355Written as Botensilimab
- Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerRecruitingPhase 1University of Southern CaliforniaNCT06336902Written as Botensilimab
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerActive, not recruitingPhase 2Agenus Inc.NCT05608044Written as Botensilimab
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedPhase 2Agenus Inc.NCT05529316Written as Botensilimab
- Combination Immunotherapy in Colorectal CancerCompletedPhase 2Weill Medical College of Cornell UniversityNCT05571293Written as Botensilimab
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingPhase 2Northwestern UniversityNCT05864534Written as Botensilimab
- FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingPhase 1/2City of Hope Medical CenterNCT05627635Written as Botensilimab
- Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior ChemotherapyActive, not recruitingPhase 1/2City of Hope Medical CenterNCT05672316Written as Botensilimab
See all 30 studies that test botensilimab →
Given beside what is tested · 7 — botensilimab is usual care or a partner of the new treatment
- BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesRecruitingPhase 2Darren Sigal, MDNCT07550088Written as Botensilimab (BOT)
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06300463Written as Botensilimab
- A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.Not yet recruitingPhase 2Nelum CorpNCT07578337Written as Botensilimab
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsRecruitingPhase 2/3The Netherlands Cancer InstituteNCT06279130Written as botensilimab
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06251973Written as Botensilimab
- Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedPhase 1Agenus Inc.NCT05377528Written as Botensilimab
- Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerCompletedPhase 1Agenus Inc.NCT04121676Written as Botensilimab
Codes
What other systems call botensilimab · ClinicalTrials.gg INT014370
- UNII (FDA) 1Z5YC3ME5NBOTENSILIMABOne source FDA
- NCI Thesaurus C158557BotensilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1Z5YC3ME5N | BOTENSILIMAB | One source FDA |
| NCI Thesaurus | C158557 | Botensilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.